NCT03929107

Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

Interleukin-7 and Chemokine (C-C Motif) -Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Wenbin Qian · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

It's a single arm, open label prospective study, in which the safety and efficacy of Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T therapy are evaluated in refractory/relapsed B cell lymphoma patients.

Conditions

• B Cell Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells	patient's T cells were seperated and engineered into Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells, and retransfused into the patient for treatment of their B cell lymphoma.

Timeline

• Start date: 2019-03-28
• Primary completion: 2022-01-31
• Completion: 2022-04-30
• First posted: 2019-04-26
• Last updated: 2019-04-26

Locations

1 site across 1 country: China